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Abstract: In this paper, the selective interactions of synthetic derivatives of two natural compounds,
berberine and palmatine, with DNA G-quadruplex structures were reported. In particular, the previous
works on this subject concerning berberine were further presented and discussed, whereas the results
concerning palmatine are presented here for the first time. In detail, these palmatine derivatives were
developed by inserting seven different small peptide basic chains, giving several new compounds
that have never been reported before. The preliminary studies of the interactions of these compounds
with various G-quadruplex-forming sequences were carried out by means of various structural and
biochemical techniques, which showed that the presence of suitable side chains is very useful for
improving the interaction of the ligands with G-quadruplex structures. Thus, these new palmatine
derivatives might act as potential anticancer drugs.
Keywords: G-quadruplex DNA; interactions; berberine and palmatine derivatives; NMR; FRET and
MST assays
1. Introduction
A G-quadruplex is a helical tertiary structure of DNA and RNA that is formed by sequences that
are particularly rich in guanine through the stacking of at least two guanine tetrad subunits. At their
own time, each of these subunits is generated by the association of four guanines in a square planar
geometry that is internally stabilized by Hoogsteen hydrogen bonds, and externally stabilized by a
cation (prevalently sodium and potassium) that is present in the physiological environment [1,2].
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G-quadruplex structures (GqS) have been widely shown to exist in the genome and in the
transcriptome including human telomeres [3], oncogenic promoters [4–6], and the 5′-untranslated
region (5′-UTR) of mRNAs [7].
Nevertheless, it has been demonstrated that GqS can inhibit the activity of telomerase, which is
an enzyme that adds telomeric repeats to the ends of chromosomes, and helps cancer proliferation [8].
GqS can also suppress the expression of specific oncogenes such as c-kit, which increases cellular
proliferation in several malignant tumors [9,10].
Hence, cancer proliferation can be hampered by small molecules that are capable of easing
G-quadruplex formation and/or stabilizing its structure.
Among all of the existing natural classes of substances, alkaloids have recently drawn huge
attention due to their potential therapeutic employments because they present high efficacy and low
systemic toxicity. As a matter of fact, these compounds possess anticancer, antiasthma, antiviral,
antiarrhythmic, analgesic, antibacterial, antihyperglycemic, and antimalarial activities [11–15].
Within this class, berberine and palmatine (Figure 1) (derived respectively from Berberis vulgaris L. [16]
and Coptis japonica (Thunb.) Makino [17]), represent the two major compounds that have been shown to
strongly inhibit telomere elongation and stabilize GqS [18,19]. From the chemical standpoint, they are
both quaternary ammonium salts, but berberine is a benzylisoquinoline alkaloid, whilst palmatine is an
isoquinoline alkaloid.
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Figure 1. Structures of berberine and palmatine. 
Previous interaction studies of these compounds have clearly revealed their weak interaction 
with DNA as well as their low selectivity and thermodynamic stability with GqS [20,21]. For these 
reasons, several efforts have been undertaken to improve their ability to stabilize G-quadruplex 
structures [22–25].  
Our research group has also focused its attention on this matter, adopting a chemical–structural 
approach. In fact, it has been widely proven that the combination of specific peptides with specific 
DNA binding scaffolds greatly increases their selectivity towards GqS versus duplex DNA. In 
particular, this selectivity is much higher if short oligonucleotides are used, because they can favor 
the linkage to the complementary DNA bases that become accessible after the formation of 
G-quadruplex structures [26]. 
First, we developed one berberine derivative that was characterized by the presence of one 
further side chain linked to the base structure [23,27]. Its synthetic pathway was extremely simple. 
Moreover, PAGE analysis, using the telomeric single-stranded DNA TSG4, showed that this 
compound was able to increase the stability of GqS more than berberine alone [23]. However, the 
same compound was able to induce only a modest increase of the melting temperature (ΔTm << 1 °C), 
as shown by a fluorescence resonance energy transfer (FRET) analysis [23].  
For this reason, we began to study palmatine and its derivatives, believing that isoquinoline 
alkaloids might show a higher affinity and specificity for GqS. In this work, the design, synthesis, 
and spectroscopic characterization of several palmatine derivatives developed in our laboratory are 
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Previous interaction studies of these compounds have clearly revealed their weak interaction
with DNA as well as their low selectivity and thermodynamic stability with GqS [20,21]. For these
reasons, several efforts have been undertaken to improve their ability to stabilize G-quadruplex
structures [22–25].
Our research group has also focused its attention on this matter, adopting a chemical–structural
approach. In fact, it has been widely proven that the combination of specific peptides with specific DNA
binding scaffolds greatly increases their selectivity towards GqS versus duplex DNA. In particular, this
selectivity is much higher if short oligonucleotides are used, because they can favor the linkage to the
complementary DNA bases that become accessible after the formation of G-quadruplex structures [26].
First, we developed one berberine derivative that was characterized by the presence of one further
side chain linked to the base structure [23,27]. Its synthetic pathway was extremely simple. Moreover,
PAGE analysis, using the telomeric single-stranded DNA TSG4, showed that this compound was able
to increase the stability of GqS more than berberine alone [23]. However, the same compound was able
to induce only a modest increase of the melting temperature (∆Tm << 1 ◦C), as shown by a fluorescence
resonance energy transfer (FRET) analysis [23].
For this reason, we began to study palmatine and its derivatives, believing that isoquinoline
alkaloids might show a higher affinity and specificity for GqS. In this work, the design, synthesis,
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and spectroscopic characterization of several palmatine derivatives developed in our laboratory are
reported for the first time, as well as the preliminary evaluations of their efficacy as stabilizers of GqS.
Several side chains have been taken into account, and an initial comparison among the different results
has also been performed. The final aim of this work was to provide a general overview and analysis of
the possible synthesis and interaction of compounds coming from natural sources that might show
potential antitumoral activities by acting on GqS.
2. Results and Discussion
Scheme 1 displays the synthetic pathway followed for the preparation of the 9-peptidyl
-palmatine derivatives.
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Scheme 1. Synthesis of the 9-peptidyl palmatine derivatives (4a–4g).
With respect to the synthetic scheme followed for berberine derivatives as reported in the work
by Franceschin et al. [23], different side chains were utilized. In particular, these peptide side chains
are described in Table 1.
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Table 1. Structures of the synthesized 9-peptidyl palmatine derivatives (4a–4g).
Ligand Peptide Side Chain
4a K-R
4b F-R
4c R-R
4d F-H-R
4e K-F-R
4f F-G-K
4g F-K-R
G = Glycine; R = Arginine; K = Lysine; H = Histidine; F = Phenylalanine.
This difference between the two protocols was derived from an extensive preliminary observation
of literature data. In fact, a previous study on this subject by Zhou et al. [28] widely demonstrated that
(1) palmatine derivatives with side chains that had terminal amino groups were able to better stabilize
GqS, thus significantly improving their inhibitory activity on telomerase, and (2) the specific presence
of amino acid chains on quinolidine structures deeply increased the ability of these compounds to
interact with GqS. These two factors proved to be extremely important, because the work has given the
model to follow in order to achieve the desired aim. The second conclusion, in particular, represented
the fundamental basis for our work. Indeed, the ring system of palmatine closely resembles that of
quindoline, and it might be expected that similar situations may lead to similar results. So, several
palmatine derivatives with peptide side chains were prepared also in order to evaluate their single
eventual contributions on the total effects.
The ability of the palmatine derivatives (compounds 4a–4g) to bind and stabilize GqS was
evaluated by several studies. First of all, in order to study the influence of the peptide side chains on
the palmatine scaffold for the different compounds, molecular docking assays (MDA) were performed
on four different parallel G-qradruplex structures formed by DNA sequences that have been thoroughly
studied in the literature: three are comprised in oncogene promoters, Bcl2, c-Kit1, and c-Myc [29,30];
whereas hTG21 [23] contains human telomeric G-rich repeats. The results were reported in Table 2,
and showed that, in general, compounds (4a–4g) possess a higher affinity of linkage with G-quadruplex
than palmatine alone.
Table 2. Docking results for palmatine and palamtine derivatives.
LIGAND Bcl-2 c-Kit1 c-Myc hTG21
4a −8.4 −10.7 −11.1 −10.7
4b −8.2 −10.3 −11.1 −9.3
4c −9.0 −10.9 −10.8 −11.6
4d −9.8 −10.8 −11.7 −11.5
4e −9.7 −11.3 −10.9 −11.3
4f −7.4 −10.3 −10.5 −10.5
4g −8.9 −10.9 −11.8 −12.0
Palmatine −2.5 −3.6 −3.09 −2.9
Compounds were docked on four different DNA strands: Bcl-2, C-Kit1, Pu22 (c-Myc), hTG21, all in parallel
conformation. Results are express in Kcal/mol.
However, the same compounds also showed a flat SAR on the different DNA strands, but this
effect could be fully explained by the well-known limitation of the technique itself. Anyway,
these values are indicative on a relative scale, and are useful for studying the behavior of similar
compounds [31]. Moreover, our results showed good accordance with the model that was already
present in the literature [32].
Figure 2 shows the specific interaction between the ligand (4a) and c-Kit1. In this case, it was
possible to observe that the core of the ligand interacts only with the aromatic area of the G-tetrad,
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while the side chain (RR) is inserted in the groove of the DNA, thus confirming the hypothesis by
Zhou et al. [28].
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A l of the synthesized compounds were also evaluated f r their thermodynamic st bility and
selectivity towards GqS with resp ct t duplex DNA. The fluorescence reso ance energy transfer
(FRET) melting technique was used. For this assay, the used G-quadruplex sequences were Fc-kit1T,
FPu18T, F21T and F10T. The sequences of these oligonucleotides are reported in Table 3.
Table 3. Specifications of the sequence of the oligonucleotides used for the fluorescence resonance
energy tra sfer (FRET) analysis.
Oligonucleotide Sequence
Fc-kit1T 5′-FAM-d[AGGGAGGGCGCTGGGAGGAGGG]-TAMRA-3′
FPu18T 5′-FAM-d[ GGTGGGGA GG GGGG]-TAMR -3′
F21T 5′-FAM-dGGGTTAGGGTTAGGGTTAGGG-TAMRA-3
F10T 5′-FAM-d[TATAGCTATA-HEG-TATAGCTATA]-TAMRA-3′
These oligonucleotides were chosen because Fc-kit1T represents the c-kit promoter DNA sequence,
FPu18T represents the oncogene c-myc promoter DNA sequence, F21T contains human G-rich
telomeric repeats, and F10T is a self-complementary duplex DNA hairpin representing a typical
non-quadruplex control [33].
Table 4 below shows the results for the palmatine derivatives (4a–4g).
Table 4. G-quadruplex DNA and duplex DNA stabilization temperatures (∆Tm) obtained from FRET
melting assay.
Ligands R a
FRET (∆Tm, ◦C)
F21T b Fc-kit1T b FPu18T b F10T b
4a KR-NH2 2.4 ± 0.8 12.3 ± 0.2 9.2 ± 0.5 0.4 ± 0.9
4b FR-NH2 11.0 ± 0.1 21.7 ± 0.8 23.8 ± 0.6 0.8 ± 0.4
4c RR-NH2 10.6 ± 0.2 21.3 ± 0.5 19.6 ± 0.9 0.3 ± 0.6
4d FHR-NH2 0.7 ± 0.7 6.5 ± 0.2 6.0 ± 1.0 0.0 ± 1.0
4e KFR-NH2 0.0 ± 1.2 6.5 ± 0.4 8.4 ± 0.3 0.1 ± 1.0
4f FGK-NH2 1.0 ± 0.6 6.1 ± 0.9 5.0 ± 1.0 0.5 ± 0.1
4g FKR-NH2 0.0 ± 1.0 6.1 ± 0.4 5.4 ± 0.2 0.1 ± 1.0
palmatine – 1.8 ± 0.2 11.6 ± 0.2 11.2 ± 0.1 0.3 ± 0.3
a Ris the peptidyl sequences of these conjugates side chains, starting from the terminal of scaffold. R, G, F, H, and K
are abbreviations of arginine, glycine, phenylalanine, histidine, and lysine, respectively. b ∆Tm = Tm (DNA + ligand)
− Tm (DNA). ∆Tm values of 0.2 µM F21T, Fc-kit1T, FPu18T, or F10T incubated with a 1.0-µM compound in the
presence of 60-mM KCl.
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The analysis revealed that all of these ligands were really able to increase the stabilization of
the G-quadruplex sequence with a wide range of ∆Tm values. In particular, the stabilizing activity
of the tested compounds was higher towards Fc-kit-1T and FPu18T G-quadruplexes than toward
the telomeric G-quadruplex F21T. In fact, the ∆Tm values of the tested compounds relative to these
oligonucleotides showed interesting and extraordinary ranges from 6.1 ◦C to 21.7 ◦C for Fc-kit-1T,
and 5.0 ◦C to 23.8 ◦C for FPu18T, whereas the telomeric G-quadruplex itself had a ∆Tm value ranges
from 0.0 ◦C to 11.0 ◦C. As a consequence, the efficacy of the stabilizing activity of the ligands on these
sequences were clearly proven.
By comparison of the FRET results among the different synthesized ligands, it was possible to
observe that compounds 4a, 4b, 4c with dipeptidyl side chains were better stabilizers than compounds
4d, 4e, 4f, 4g, which presented a further amino acid residue on the peptide chains. This observation
allowed us to establish, from an experimental point of view, that the side chains with more than two
amino acids on palmatine derivatives did not increase the ability of the compound to stabilize GqS,
but rather had the opposite effect. In fact, they greatly reduced it.
It is very likely that this depends on the size of the loop and the different ability of the ligand
to be accommodated with its peptide basic side chain in the GqS, which is absolutely essential for
the stabilization of the entire structure. However, an important gain in the selectivity towards the
G-quadruplex with respect to the duplex for most of the synthesized compounds was observed.
After that, the microscale thermophoresis assay (MST) was used to further investigate the binding
affinity of ligands for Fc-kit1T. In addition, the same technique was used to investigate their level of
specificity for Fc-kit1T against duplex DNA. In fact, MST is a highly sensitive technique that acts as a real
probe for many kinds of binding-induced interactions such as molecular size, charge, hydration shell,
or conformation [34], and possesses several advantages, including easy implementation, high speed
(about 1 min), low sample requirements (e.g., microliter volumes), no limitations on the molecular size
or weight of the binding partners, and the possibility of using several buffer solutions [35].
Tables 5 and 6 show the results of this analysis.
As shown, all of the tested ligands were found to bind to Fc-kit1T more tightly than duplex DNA.
The dissociation constants (Kd) for Fc-kit1T were between 1.41 µM and 11.1 µM against 10.7–45.5 µM
for the duplex DNA. From these data, it could be clearly deduced that the introduction of peptidyl
side chains on the scaffold of palmatine gave a moderate improvement of its specificity towards the
quadruplex with respect to duplex DNA with a good increase of the Kdduplex/KdFc-kit1Tstarting from
the value of 1.6 associated to palmatine. In particular, the ligands 4a, 4b, 4c with Kdduplex/KdFc-kit1T
values ranging from 7.6 to 13.9 showed higher affinity and selectivity towards Fc-kit1T than the ligands
4d, 4e, 4f, 4g, which had Kdduplex/KdFc-kit1T values ranging from 2.1 to 4.2. Yet, it was not possible to
verify whether this result was part of a general tendency, because only one sequence was completely
studied. Further studies in this field should be performed.Anyway, these preliminary results were in
good accordance with those obtained from FRET analysis, thus making all of these ligands potential
good compounds for the stabilization of GqS and, by consequence, potential good antitumor agents.
Table 5. Kinetic constants of palmatine derivatives with Fc-kit1T and duplex DNA by microscale
thermophoresis (MST) assay.
Compounds R a Fc-kit1T(Kd, µM) Duplex(Kd, µM) Kdduplex/Kdc-kit1
4a KR-NH2 2.65 ± 0.33 23.60 ± 1.07 8.9
4b FR-NH2 1.41 ± 0.09 10.70 ± 1.30 7.6
4c RR-NH2 1.47 ± 0.12 20.40 ± 0.96 13.9
4d FHR-NH2 9.68 ± 0.57 40.70 ± 5.87 4.2
4e KFR-NH2 8.00 ± 0.89 16.80 ± 1.38 2.1
4f FGK-NH2 11.10 ± 0.51 40.70 ± 1.62 3.7
4g FKR-NH2 6.60 ± 0.472 45.50 ± 4.57 6.9
palmatine – 3.25 ± 0.32 5.08 ± 0.34 1.6
a R is the peptidyl sequences of these conjugates side chains, starting from the terminal of scaffold. R, G, F, H, and K
are abbreviations of arginine, glycine, phenylalanine, histidine, and lysine, respectively.
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Table 6. Energetic values of the bond between palmatine derivatives with c-kit1, c-Myc and Htg21
G-quadruplex structures by MST assay.
Ligands R a
Bond Energy (kcal/mol)
Htg21 Fc-kit1T c-Myc
4a KR-NH2 −10.7 −10.7 −11.8
4b FR-NH2 −9.9 −10.3 −11.1
4c RR-NH2 −11.3 −10.8 −10.7
4d FHR-NH2 −11.6 −10.8 −11.3
4e KFR-NH2 −11.3 −11.3 −10.9
4f FGK-NH2 −10.5 −10.3 −10.5
4g FKR-NH2 −12.0 −10.9 −11.8
palmatine – −2.9 −3.5 −3.1
a Ris the peptidyl sequences of these conjugates side chains, starting from the terminal of scaffold. R, G, F, H, and K
are abbreviations of arginine, glycine, phenylalanine, histidine, and lysine, respectively.
3. Materials and Methods
3.1. Materials
Pure palmatine was purchased from Sigma-Aldrich () (Darmstadt, Germany) as well as the
other natural solvents of RPE purity grade, if not diversely specified, and the deuterated solvents.
The Fmoc-protected amino acids and Rink amide AM resin were purchased from GL Biochem
(Shanghai, China) Ltd. All of the oligomers/primers were purchased from Invitrogen and Sangon
Biotech (Shanghai, China). Stock solutions of all of the derivatives (10 mM) were made using DMSO
(10%) or double-distilled deionized water. Silica gel for classical column chromatography (40–63 µm
particle size) was purchased from Fluka Analytical (St. Gallen, Switzerland), while silica gel for flash
column chromatography (200–300 mesh, was purchased from Qingdao Haiyang Chemical Co. Ltd.
(Qingdao, Shandong, China).
3.2. Instrumentation
1H-NMR and 13C-NMR spectra were recorded on a Varian (now Agilent Technologies, Santa Clara,
CA, USA) Mercury 300 MHz spectrometer and/or on a Bruker BioSpin GmbH 400 MHz spectrometer
(Billerica, MA, USA) using CD3OD and DMSO-d6 as deuterated solvents. The chemical shifts were
expressed from the internal solvent signal of CD2HOD (m5, 3.31 ppm) for spectra in CD3OD, while
the internal solvent signal of D3SOD3 (p, 2.50 ppm) was the reference for spectra in DMSO-d6.
Mass spectra were, instead, recorded on a Shimadzu LCMS-2010A instrument or on a Q-TOF
MICRO spectrometer (Micromass, now Waters, Manchester, UK) instrument. The first instrument
used an ESI-API (electrospray ionization–atmospheric pressure ionization) source, whereas the
second instrument used only an ESI source. Both instruments operated in positive ionization with a
voltage of 5000 V. The flow rates of sample infusion for both instruments were 30 µL/min, with 50
acquisitions per spectrum. Data coming from both instruments were analyzed by using the MassLynx
software developed by Waters. High-resolution mass spectra (HRMS) were performed on a Shimadzu
LCMS-IT-TOF instrument (Kyoto, Japan) with the same characteristics as previously described.
The purification of the reaction mixtures was achieved by means of classical column chromatography
on silica gel, by means of flash column chromatography or by means of inverse column chromatography
with stationary phase (C18)-bonded silica (USP classification L1). The purification of all of the tested
compounds was carried out through a preparative HPLC using a Varian Pro Star equipped with an
UV-vis detector (BioRad, Santa Clara, CA, USA) and a Phenomenex C18 (10.0 × 250 mm, 5 µm) column.
The microwave reaction was performed with Biotage Initiatior (Biotage, Uppsala, Sweden).
The radioactivity was quantified by using a Beckman LS 5000 TD Scintillation System (Dickinson,
TX, USA).
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3.3. Synthesis of the Peptide Side Chains
Peptide side chains were synthesized by using a solid-phasemethodology through a manual
operation of the peptide synthesizer. The Fmoc protected various amino acids (four equivalent ratio
excess to the resin) were coupled orderly to the Rink Amide AM resin (500 mg) by using DIC/HOBT
(190 mg/200 mg) in DMF (4 mL) for 3 h. The deprotection of the Fmoc group was carried out with
piperidine/DMF 25% (2 mL) for 30 min.
3.4. Synthesis of Palmatine Derivatives
The synthesis of the palmatine derivatives (compounds 4a–4g) was achieved by using a similar
procedure as reported in the literature for berberine [22], but with some modifications. In particular,
the first step was optimized for the microwave reaction by increasing the quantity of the reagent,
while the purification was performed on an inverse chromatographic column by using a mixture of
CH3OH/H2Owith 1% of TFA from 5:95 (v/v) to 1:1 (v/v).
Reaction 1: The reaction was performed under microwave irradiation. A quantity of palmatine
for the weight of 2.0 g (5.15 mmol) was added in a flask provided with a stir bar. The solution was
pre-stirred for 1 min before raising the temperature. The machine was programmed to high levels of
absorption. The solution was heated to 180 ◦C, with a voltage of 400 W, for 5–10 min. The reaction
gave a red precipitate, compound (1), which was washed and filtered with ether under vacuum with a
final yield of 95%.
Reaction 2: Compound (1) present in CH2Cl2 was treated with the ethyl ester of bromoacetic
acid in a ratio of 1:2 (v/v), stirred on a magnetic stirrer, and refluxed for 12 h, as suggested in the
literature [36]. The resulting yellow precipitate was filtered off, refluxed with EtOH for 30 min, cooled,
filtered off again, and dried in a vacuum to give compound (2) with a yield of 55%.
Reaction 3: Compound (2) was dissolved in a solution of CH3OH/H2O (1:1 (v/v)). Then, NaOH
in a ratio of 1:2 (w/w) was added under reflux for 12 h on a water bath, and the solution was cooled [36].
At this point, HCl was added until a pH value of 1 was obtained. The resulting yellow precipitate was
filtered off and dried in a vacuum to give compound (3) with a yield of 45%.
Reaction 4: To have compounds (4a–4g), the intermediate compound (3) for the weight of 200 mg
was mixed with deprotected peptidyl side chains using DIC/HOBT (475 mg/500 mg) in DMF (4 mL)
with shaking for 12 h. After coupling with compound (3), the resin was treated with the cleavage
reagent (95% TFA, 5% dd H2O (v/v)) for 2 h, washed with dry ether (30 mL), and then evaporated under
vacuum. The crude products were purified by using preparative RP-HPLC with CH3CN/H2O (95:5 to
5:95) containing 0.1% TFA at a flow rate of 2.5 mL/min elution, and then lyophilized to give the final
compounds. For compound (4a), the peptidyl coupling order is lysine-arginine, and this was a yellow
solid with a yield of 10%. For compound (4b), the peptidyl coupling order was phenylalanine-arginine,
and it was a yellow solid with a 29% yield. For compound (4c), the peptidyl coupling order was
arginine–arginine, and it was a yellow solid with a 5% yield. For compound (4d), the peptidyl coupling
order was phenylalanine–histidine–arginine, and it was a yellow solid with a 5% yield. For compound
(4e), the peptidyl coupling order was lysine-phenylalanine-arginine–, and it was a yellow solid with
a 10% yield. For compound (4f), the peptidyl coupling order was phenylalanine-glycine-lysine,
and it was a yellow solid with an 8% yield. For compound (4g), the peptidyl coupling order was
phenylalanine-lysine-arginine e, and it was a yellow solid with a 10% yield.
3.5. NMR and MS Data of Compounds (* = IUPAC Names)
3-Hydroxy-2,16,17-trimethoxy-11,12-dihydroisoquinolino[9,8-a]isoquinolin-7-ium chloride (1) (Figure 3):
1H-NMR (400 MHz, DMSO) δ: 9.11 (1H, s, H-7), 8.08 (1H, s, H-10), 7.52 (1H, s, H-18), 7.24 (1H, t,
J = 6.4 Hz, H-6), 6.99 (1H, s, H-15), 6.40 (1H, d, J = 6.4 Hz, H-1), 4.50 (2H, t, J = 4.4 Hz, H-11), 3.90 (3H,
s, OCH3-17), 3.83 (3H, s, OCH3-16), 3.74 (3H, s, OCH3-2), 3.07 (2H, t, J = 4.4Hz, H-12). ESI-API-MS:
m/z 338.1 [M]+ (calculated for C20H20NO4, 338.4 [M]+).
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3-(2-Ethoxy-2-oxoethoxy)-2,16,17-trimethoxy-11,12-dihydroisoquinolino[9,8-a]isoquinolin-7-ium (2) (Figure 3):
1H-NMR (400 MHz, DMSO) δ: 9.93 (1H, s, H-7), 9.02 (1H, s, H-10), 8.20 (1H, d, J = 8.2 Hz, H-6), 8.02
(1H, d, J = 8.2 Hz, H-1), 7.71 (1H, s, H-18), 7.10 (1H, s, H-15), 5.06 (2H, s, H-19), 4.94 (2H, t, J = 4.9 Hz,
H-11), 4.17 (2H, q,J = 4.1 Hz, H-21), 4.03 (3H, s, OCH3-17), 3.93 (3H, s, OCH3-16), 3.87 (3H, s, OCH3-2),
3.22 (2H, t, J = 4.9 Hz, H-12), 1.19 (3H, t, J = 4.1 Hz, H-23). ESI-API-MS: m/z 424.3 [M]+ (calculated for
C24H27NO6, 424.5 [M]+).
3-(Carboxymethoxy)-2,16,17-trimethoxy-11,12-dihydroisoquinolino[9,8-a]isoquinolin-7-ium (3) (Figure 3):
1H-NMR: (400 MHz, DMSO) δ: 10.40 (1H, s, H-7), 8.98 (1H, s, H-10), 7.59 (1H, d, J = 8.2 Hz, H-6), 7.49
(1H, d, J = 8.2 Hz, H-1), 7.43 (1H, s, H-18), 6.94 (1H, s, H-15), 4.87 (2H, t, J = 4.9 Hz, H-11), 4.26 (2H,
s, H-19), 3.88 (3H, s, OCH3-17), 3.87 (3H, s, OCH3-16), 3.82 (3H, s, OCH3-2), 3.22 (2H, t, J = 4.9 Hz,
H-12).ESI-API-MS: m/z 396.1 [M]+ (calculated for C22H23NO6, 396.4 [M]+).
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Figure 3. Structures of compounds (1–3). 
3-(2-(((S)-6-Amino-1-(((S)-1-amino-5-guanidino-1-oxopentan-2-yl)amino)-1-oxohexan-2-yl)amino)-2-oxoeth
oxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium* (4a) (Figure 4): 1H-NMR (400 
MHz, CD3OD) δ: 9.95 (1H, s, H-7), 8.83 (1H, s, H-10), 8.16 (1H, d, J = 8.0 Hz, H-6), 8.14 (1H, d, J = 8.0 
Hz, H-1), 7.68 (1H, s, H-18), 7.06 (1H, s, H-15), 6.09 (2H, t, J = 6.1 Hz, H-11), 4.39 (1H, m, H-22), 4.26 
(1H, m, H-29), 4.13 (3H, s, OCH3-17), 4.07 (2H, m, H-34), 4.00 (3H, s, OCH3-16), 3.95 (3H, s, OCH3-2), 
3.22 (2H, t, J = 6.0 Hz, H-12), 3.20 (2H, m, H-26), 1.71 (10H, m, H-23, H-24, H-25, H-32, H-33). 
HR-MS(LC-MS-IT-TOF): m/z 580.6512 [M]+. 
i r . tr t r f ( ).
3-(2-(((S)-6-Amino-1-(((S)-1-amino-5-guanidino-1-oxopentan-2-yl)amino)-1-oxohexan-2-yl)amino)-2-oxoeth
oxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium* (4a) (Figure 4): 1H-NMR (400 MHz,
CD3OD) δ: 9.95 (1H, s, H-7), 8.83 (1H, s, H-10), 8.16 (1H, d, J = 8.0 Hz, H-6), 8.14 (1H, d, J = 8.0 Hz,
H-1), 7.68 (1H, s, H-18), 7.06 (1H, s, H-15), 6.09 (2H, t, J = 6.1 Hz, H-11), 4.39 (1H, m, H-22), 4.26 (1H,
m, H-29), 4.13 (3H, s, OCH3-17), 4.07 (2H, m, H-34), 4.00 (3H, s, OCH3-16), 3.95 (3H, s, OCH3-2),
3.22 (2H, t, J = 6.0 Hz, H-12), 3.20 (2H, m, H-26), 1.71 (10H, m, H-23, H-24, H-25, H-32, H-33).
HR-MS(LC-MS-IT-TOF): m/z 580.6512 [M]+.
9-(3-(((S)-1-(((S)-1-Amino-6-guanidino-1-oxohexan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-oxopropyl)
-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium* (4b) (Figure 4): 1H-NMR (400 MHz,
CD3OD) δ: 9.96 (1H, s, H-7), 8.72 (1H, s, H-10), 8.14 (1H, d, J = 8.0 Hz, H-6), 8.05 (1H, d, J = 8.0 Hz,
H-1), 7.66 (1H, s, H-18), 7.15 (5H, m, H-25, H-26, H-27, H-28, H-29), 7.05 (1H, s, H-15), 6.11 (2H, t,
J = 6.0 Hz, H-11), 4.95 (2H, s, H-19), 4.47 (1H, m, H-31), 4.13 (3H, s, OCH3-17), 4.12 (3H, s, OCH3-16),
4.09 (3H, s, OCH3-2), 4.07 (2H, m, H-35), 3.16 (2H, d, J = 6.0 Hz, H-12), 1.71 (4H, m, H-23, H-33).
HR-MS(LC-MS-IT-TOF): m/z 698.3296 [M]+.
3-(2-(((S)-5-((1-Aminovinyl)amino)-1-oxo-1-(((S)-2-oxo-6-(prop-1-en-2-ylamino)hexan-3-yl)amino)pentan-2-yl)am
ino)-2-oxoethoxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino [3,2-a]isoquinolin-7-ium* (4c) (Figure 4): 1H-NMR
(400 MHz, CD3OD) δ: 9.96 (1H, s, H-7), 8.72 (1H, s, H-10), 8.14 (1H, d, J = 8.0 Hz, H-6), 8.05 (1H, d,
J = 8.0 Hz, H-1), 7.66 (1H, s, H-18), 7.05 (1H, s, H-15), 6.04 (2H, t, J = 6.0 Hz, H-11), 4.95 (2H, s, H-19), 4.69
(1H, m, H-30), 4.47 (1H, m, H-22), 4.13 (3H, s, OCH3-17), 4.12 (3H, s, OCH3-16), 4.09 (3H, s, OCH3-2), 4.07
(4H, m, H-25, H-34), 3.16 (2H, d, J = 6.0 Hz, H-12), 1.87 (4H, m, H-23, H-32), 1.71 (4H, m, H-24, H-33).
HR-MS(LC-MS-IT-TOF): m/z 707.3623 [M]+.
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Figure 4. Structures of compounds (4a–4c). 
9-(2-(((S)-1-(((S)-1-(((S)-1,6-Diamino-1-oxohexan-2-yl)amino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)amin
o)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethoxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquin
olin-7-ium* (4d) (Figure 5): 1H-NMR: (400 MHz, CD3OD) δ: 9.89 (1H, s, H-7), 8.78 (1H, s, H-10), 8.16 
(1H, d, J = 8.0 Hz, H-6), 8.10 (1H, d, J = 8.0 Hz, H-1), 7.99 (1H, s, H-36), 7.70 (1H, s, H-18), 7.20 (5H, m, 
H-25, H-26, H-27, H-28, H-29), 7.08 (1H, s, H-15), 7.05 (1H, s, H-35),6.09 (2H, t, J = 6.0 Hz, H-11), 4.95 
(2H, s, H-19), 4.71 (1H, m, H-30), 4.54 (1H, m, H-22), 4.36 (1H, m, H-38), 3.97 (3H, s, OCH3-17), 3.93 
(3H, s, OCH3-16), 3.88 (3H, s, OCH3-2), 3.91 (2H, s, H-32), 3.79 (2H, m, H-23), 3.20 (2H, m, H-42), 3.18 
(2H, t, J = 6.0 Hz, H-12), 1.90 (2H, m, H-41), 1.71 (2H, m, H-40). HR-MS(LC-MS-IT-TOF): m/z 835.9367 
[M]+. 
9-(((6S,9S,12S)-1-Amino-12-(4-aminobutyl)-9-benzyl-6-carbamoyl-1-imino-8,11,14-trioxo-2,7,10,13-tetraaz
apentadecan-15-yl)oxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium* (4e) (Figure 5): 
1H-NMR (400 MHz, CD3OD) δ: 9.96 (1H, s, H-7), 8.73 (1H, s, H-10), 8.13 (1H, d, J = 8.0 Hz, H-6), 8.05 
(1H, d, J = 8.0 Hz, H-1), 7.50 (1H, s, H-18), 7.22 (5H, m, H-34, H-35, H-36, H-37, H-38), 7.12 (1H, s, 
H-15), 6.05 (2H, t, J = 6.0 Hz, H-11), 4.96 (2H, s, H-19), 4.81 (1H, m, H-29), 4.74 (1H, m, H-22), 4.66 (1H, 
m, H-39), 4.02 (3H, s, OCH3-17), 4.01 (3H, s, OCH3-16), 3.98 (3H, s, OCH3-2), 3.81 (2H, m, H-43), 3.27 
(2H, m, H-32), 3.21 (2H, m, H-23), 3.20 (2H, m, H-26), 3.03 (2H, t, J = 6.0 Hz, H-12), 1.90 (4H, m, H-42), 
1.71 (2H, m, H-24, H-41), 1.65 (2H, m, H-25). HR-MS (LC-MS-IT-TOF): m/z 826.4581 [M]+. 
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9-(2-(((S)-1-(((S)-1-(((S)-1,6-Diamino-1-oxohexan-2-yl)amino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)amino)
-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethoxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin
-7-ium* (4d) (Figure 5): 1H-NMR: (400 MHz, CD3OD) δ: 9.89 (1H, s, H-7), 8.78 (1H, s, H-10), 8.16 (1H, d,
J = 8.0 Hz, H-6), 8.10 (1H, d, J = 8.0 Hz, H-1), 7.99 (1H, s, H-36), 7.70 (1H, s, H-18), 7.20 (5H, m, H-25,
H-26, H-27, H-28, H-29), 7.08 (1H, s, H-15), 7.05 (1H, s, H-35),6.09 (2H, t, J = 6.0 Hz, H-11), 4.95 (2H, s,
H-19), 4.71 (1H, m, H-30), 4.54 (1H, m, H-22), 4.36 (1H, m, H-38), 3.97 (3H, s, OCH3-17), 3.93 (3H, s,
OCH3-16), 3.88 (3H, s, OCH3-2), 3.91 (2H, s, H-32), 3.79 (2H, m, H-23), 3.20 (2H, m, H-42), 3.18 (2H, t,
J = 6.0 Hz, H-12), 1.90 (2H, m, H-41), 1.71 (2H, m, H-40). HR-MS(LC-MS-IT-TOF): m/z 835.9367 [M]+.
9-(((6S,9S,12S)-1-Amino-12-(4-aminobutyl)-9-benzyl-6-carbamoyl-1-imino-8,11,14-trioxo-2,7,10,13-tetraazapen
tadecan-15-yl)oxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium* (4e) (Figure 5): 1H-NMR
(400 MHz, CD3OD) δ: 9.96 (1H, s, H-7), 8.73 (1H, s, H-10), 8.13 (1H, d, J = 8.0 Hz, H-6), 8.05 (1H, d,
J = 8.0 Hz, H-1), 7.50 (1H, s, H-18), 7.22 (5H, m, H-34, H-35, H-36, H-37, H-38), 7.12 (1H, s, H-15), 6.05 (2H,
t, J = 6.0 Hz, H-11), 4.96 (2H, s, H-19), 4.81 (1H, m, H-29), 4.74 (1H, m, H-22), 4.66 (1H, m, H-39), 4.02 (3H, s,
OCH3-17), 4.01 (3H, s, OCH3-16), 3.98 (3H, s, OCH3-2), 3.81 (2H, m, H-43), 3.27 (2H, m, H-32), 3.21 (2H, m,
H-23), 3.20 (2H, m, H-26), 3.03 (2H, t, J = 6.0 Hz, H-12), 1.90 (4H, m, H-42), 1.71 (2H, m, H-24, H-41), 1.65
(2H, m, H-25). HR-MS (LC-MS-IT-TOF): m/z 826.4581 [M]+.
9-(2-(((S)-1-((2-(((S)-1,6-Diamino-1-oxohexan-2-yl)amino)-2-oxoethyl)amino)-1-oxo-3-phenylpropan-2-yl)
amino)-2-oxoethoxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium* (4f) (Figure 5):
1H-NMR (400 MHz, CD3OD) δ: 9.94 (1H, s, H-7), 8.74 (1H, s, H-10), 8.13 (1H, d, J = 8.0 Hz, H-6), 8.06
(1H, d, J = 8.0 Hz, H-1), 7.75 (1H, s, H-18), 7.23 (5H, m, H-25, H-26, H-27, H-28, H-29), 7.12 (1H, s,
H-15), 6.04 (2H, t, J = 6.0 Hz, H-11), 4.92 (2H, s, H-19), 4.70 (1H, m, H-31), 4.41 (1H, m, H-22), 4.09 (2H,
s, H-29), 3.99 (3H, s, OCH3-17), 3.97 (3H, s, OCH3-16), 3.94 (3H, s, OCH3-2), 3.61 (2H, m, H-36), 3.13
(2H, t, J = 6.0 Hz, H-12), 3.08 (2H, m, H-23), 1.92 (2H, m, H-34), 1.70 (2H, m, H-33), 1.45 (2H, m , H-35).
HR-MS(LC-MS-IT-TOF): m/z 727.8355 [M]+.
9-(((6S,9S,12S)-1-Amino-9-(4-aminobutyl)-12-benzyl-6-carbamoyl-1-imino-8,11,14-trioxo-2,7,10,13-tetraazapen
tadecan-15-yl)oxy)-2,3,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium* (4g) (Figure 5): 1H-NMR
(400 MHz, CD3OD) δ: 9.98 (1H, s, H-7), 8.69 (1H, s, H-10), 8.15 (1H, d, J = 8.0 Hz, H-6), 8.04 (1H, d,
J = 8.0 Hz, H-1), 7.51 (1H, s, H-18), 7.27 (5H, m, H-25, H-26, H-27, H-28, H-29), 7.12 (1H, s, H-15), 6.04 (2H,
t, J = 6.0 Hz, H-11), 4.94 (2H, s, H-19), 4.80 (1H, m, H-22), 4.73 (1H, m, H-29), 4.69 (1H, m, H-35), 4.05 (3H, s,
OCH3-17), 4.06 (3H, s, OCH3-16), 3.95 (3H, s, OCH3-2), 3.71 (2H, m, H-38), 3.21 (2H, m, H-23), 3.20 (2H, m,
H-33), 3.02 (2H, t, J = 6.0 Hz, H-12), 1.90 (4H, m, H-32, H-37), 1.70 (4H, m, H-31, H-36), 1.65 (2H, m, H-30).
HR-MS(LC-MS-IT-TOF): m/z 826.4537 [M]+.
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3.6. Structural and Biological Analysis  
3.6.1. Molecular Docking 
The crystal structures of G-quadruplex DNA were extracted from the Protein Data Bank (PDB; 
PDB) and are reported in Table 7.  
Table 7. G-quadruplex structures used in molecular docking. PDB: Protein Data Bank. 
G-quadruplex name PDB ID 
c-myc parallel 1XAV 
c-kit parallel 2O3H 
Bcl-2 parallel 2F8U 
Htg21 parallel 2KZE 
The structures were treated with the Maestro module of Schrödinger Suite 2012 as follows: all 
of the sulfate ions and water molecules found in the structure were removed, hydrogen atoms were 
added, and the H-bond assignment was optimized with exhaustive sampling. 
Ligand structures were constructed and optimized by using the Maestro 9.3 followed by 
rebuilding the three-dimensional (3D) conformation of each molecule using LigPrep 2.3 at pH of 
7.0. Afterwards, the rebuilt ligands were subjected to a conformational search using Macromodel 
9.7 with an OPLS 2005 force field in a water solvent model. For each DNA, first, a grid box of 36 × 
36 × 36 Å with a default inner box (10 × 10 × 10 Å) was centered on the DNA itself.  
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3.6. Structural and Biological Analysis
3.6.1. olecular Docking
The crystal structures of G-quadruplex D A ere extracted fro the Protein Data Bank (PDB;
PDB) and are reported in Table 7.
Table 7. -quadruplex structures used in olecular docking. P B: Protein ata Bank.
G-quadruplex Name PDB ID
c-myc parallel 1XAV
c-kit parallel 2O3H
Bcl-2 parallel 2F8U
Htg21 parallel 2KZE
The structures were treated with the Maestro module of Schrödinger Suite 2012 as follows: all
of the sulfate ions and water molecules found in the structure were removed, hydrogen atoms were
added, and the H-bond assignment was optimized with exhaustive sampling.
Ligand structures were constructed and optimized by using the Maestro 9.3 followed by rebuilding
the three-dimensional (3D) conformation of each molecule using LigPrep 2.3 at pH of 7.0. Afterwards,
the rebuilt ligands were subjected to a conformational search using Macromodel 9.7 with an OPLS
2005 force field in a water solvent model. For each DNA, first, a grid box of 36 × 36 × 36 Å with a
default inner box (10 × 10 × 10 Å) was centered on the DNA itself.
For all of the experiments, the standard precision mode of GlideScore was selected as the scoring
function. The top 10 poses were kept, and XP score functions between the ligands and the DNA
were analyzed.
3.6.2. FRET Assay
FRET assay was carried out on a real-time PCR apparatus following previously published
procedures [37].
The fluorescently-labeled oligonucleotides used as FRET probes (F21T, Fc-kit1T, FPu18T, the donor
fluorophore 6-carboxyfluorescein (FAM), and the acceptor fluorophore 6-carboxytetramethylrhodamine
(TAMRA)) were diluted from stock to the correct concentration (800 nM) in a 0.5-mM potassium
cacodylate buffer (pH 7.4) with 100 mM of LiCl, and then annealed by heating to 85 ◦C for 10 min,
Molecules 2018, 23, 1423 12 of 14
followed by slowly cooling down to room temperature in the heating block. Fluorescence melting
curves were determined with a Roche LightCycler 2 real-time PCR apparatus, using a total reaction
volume of 20 µL with 0.2 µM of fluorescently labeled oligonucleotides (prepared as described before)
in the presence or absence of 2 µM of every compound. Fluorescence readings with excitation at
470 nm and detection at 530 nm were taken at intervals of 1 ◦C over the range 37–99 ◦C, with a constant
temperature being maintained for 30 s prior to each reading to ensure a stable value. Final analysis of
the data was carried out using Origin8.0 (OriginLab Corp, Northampton, MA, USA).
3.6.3. MST Assay
The fluorescently labeled oligonucleotides were diluted from stock to the required concentration
(10 µM) in 10 mM of Tris-HCl buffer, pH 7.4, in the presence of 100 mM of KCl, and then annealed
by heating at 95 ◦C for five minutes, gradually cooled to room temperature, and incubated at 4 ◦C
overnight. The ligand concentration varied from 0 µM to 200 µM for tested the KD of duplex DNA.
A 16-point dilution series was prepared for each DNA. After incubation, the samples were loaded into
MST standard-treated glass capillaries. The binding affinity study was investigated on the microscale
thermophoresis instrument (NanoTemper Tchnologies GmbH, Munich, Germany). The value of Kd
was calculated by NT ANALYSIS SOFTWARE provided by NanoTemper Technologies GmbH (Munich,
Germany).
4. Conclusions
The chemical synthesis of seven new palmatine derivatives was successfully carried out with
few steps and not bad yields. The preliminary FRET and MST assays clearly showed how the further
presence of side chains on the core structure of these compounds is important in order to improve their
interaction with GqS and increase the stability of the complex structures formed. This latter aspect is
extremely important, because this may represent the base of action to treat several tumors. Therefore,
the future perspectives are promising for the hope to finally find the perfect compound with the best
anticancer activity.
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